Plinio Cirillo
Overview
Explore the profile of Plinio Cirillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
1240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pepe M, Tritto R, Napoli G, Giordano S, Romito R, Biondi-Zoccai G, et al.
J Cardiovasc Pharmacol
. 2025 Feb;
PMID: 39933047
The management of antiplatelet therapy in coronary artery disease (CAD) is one of the most debated topics in cardiology. In some clinical scenarios, such as acute coronary syndromes (ACS) and/or...
2.
Di Serafino L, Scalamogna M, Carbone C, De Rosa M, Mitrano L, Cirillo P, et al.
Circ Cardiovasc Interv
. 2025 Feb;
:e014543.
PMID: 39895505
No abstract available.
3.
de Sio V, Gragnano F, Capolongo A, Guarnaccia N, Maddaluna P, Acerbo V, et al.
Int J Cardiol
. 2025 Jan;
423:133028.
PMID: 39890028
Aims: Semaglutide has been shown to reduce cardiovascular events in non-diabetic patients with preexisting cardiovascular disease and overweight/obesity in the SELECT trial. Data on the applicability of these results to...
4.
Piccolo R, Calabro P, Carrara G, Varricchio A, Baldi C, Napolitano G, et al.
EuroIntervention
. 2025 Jan;
21(1):58-72.
PMID: 39773824
Background: Few data are available on polymer-free drug-eluting stents in patients undergoing percutaneous coronary intervention (PCI). Aims: We aimed to determine the efficacy and safety of a polymer-free amphilimus-eluting stent...
5.
Angellotti D, Losi M, Immobile Molaro M, Ilardi F, Manzo R, Nappa D, et al.
JACC Case Rep
. 2024 Dec;
29(21):102696.
PMID: 39619041
In patients with severe left ventricle hypertrophy and aortic stenosis, the presence of intraventricular gradient should always be investigated. Its prompt recognition enables a precise diagnosis and safe treatment of...
6.
Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabro P, et al.
JACC Cardiovasc Interv
. 2024 Oct;
17(20):2325-2336.
PMID: 39477636
Over the past decades, there have been great advancements in the antithrombotic management of patients undergoing percutaneous interventions, but most of the available evidence derives from studies conducted in the...
7.
Ilardi F, Franzone A, Iapicca C, Manzo R, Angellotti D, Nappa D, et al.
J Cardiovasc Med (Hagerstown)
. 2024 Oct;
25(12):836-844.
PMID: 39445522
Purpose: The prognostic significance of noninvasive myocardial work (MW) indices in patients undergoing transcatheter aortic valve implantation (TAVI) has not been adequately examined. Methods: We retrospectively selected 88 consecutive patients...
8.
Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabro P, et al.
JACC Cardiovasc Interv
. 2024 Oct;
17(19):2197-2215.
PMID: 39415380
Antithrombotic therapy after cardiac percutaneous interventions is key for the prevention of thrombotic events but is inevitably associated with increased bleeding, proportional to the number, duration, and potency of the...
9.
Benenati S, Gragnano F, Scalamera R, de Sio V, Capolongo A, Cesaro A, et al.
Int J Cardiol
. 2024 Sep;
417():132568.
PMID: 39284439
Background: Tools for precise prediction of bleeding risk in patients undergoing percutaneous coronary intervention (PCI) with cangrelor are lacking. Methods: Consecutive patients undergoing PCI and treated with cangrelor in 7...
10.
Manzi L, Florimonte D, Forzano I, Buongiorno F, Sperandeo L, Castiello D, et al.
Interv Cardiol Clin
. 2024 Sep;
13(4):527-541.
PMID: 39245552
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is fundamental in all patients undergoing percutaneous coronary intervention (PCI) to prevent coronary thrombosis. In patients with atrial fibrillation (AF), an...